Cargando…
Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives
Esophageal cancer is the sixth most common cause of cancer-related mortality worldwide. The standard treatment for unresectable esophageal cancer is systemic chemotherapy. However, the survival benefit is limited, with a median overall survival of less than 10 months. The advent of immune checkpoint...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746438/ https://www.ncbi.nlm.nih.gov/pubmed/36375821 http://dx.doi.org/10.1080/21645515.2022.2143177 |